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The aims of this study were to investigate the inﬂuence of serotonin (5-HT) on the eﬀects of intra-articular injections of gluco-
corticoid on pain of the temporomandibular joint (TMJ) in patients with inﬂammatory disorders of the TMJ. The pretreatment
synovial ﬂuid 5-HT was negatively, and plasma 5-HT positively, correlated to change in TMJ pain after treatment. The pretreatment
plasma 5-HT was positively correlated to change in pressure-pain threshold after treatment. In conclusion, this study shows that
local and systemic serotonergic mechanisms partly determine the eﬀect of intra-articular glucocorticoid treatment on TMJ pain
in patients with chronic TMJ arthritis of systemic nature, while change in pressure-pain threshold over the TMJ is inﬂuenced by
systemic serotonergic mechanisms.
INTRODUCTION
Glucocorticoids administered locally or systemically
suppress inﬂammation and pain in rheumatoid arthritis
[1, 2]. Glucocorticoids pass through the cellular mem-
brane and bind to glucocorticoid receptors in the cy-
toplasm. Activated receptors inhibit the expression of
genes for proinﬂammatory cytokines, enzymes, recep-
tors, and adhesion molecules, while increasing the ex-
pression of genes coding for antiinﬂammatory proteins
like interleukin-10 and interleukin-1 receptor antagonist
[2]. However, there is no report whether glucocorticoid
inhibits release of serotonin (5-HT) from, for example,
thrombocytes or mast cells or whether local or systemic
serotonergic mechanisms inﬂuence the response to local
glucocorticoid administration of peripheral joint pain.
Treatment with intra-articular glucocorticoid of the
temporomandibular joint (TMJ) has proved eﬃcient in
pain,tendernesstodigitalpalpationofthelateralaspectof
the joint, and mobility 4–6 weeks after administration in
patients with rheumatoid arthritis (RA; [1, 3]). Another
study reported that only resting pain relief remained af-
ter 5 weeks, while pressure-pain threshold and movement
painhadreturnedtothepretreatmentlevel[3].Glucocor-
ticoids might therefore exert diverse eﬀects on diﬀerent
pain entities [4] such as resting pain, pain on joint move-
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ment, tenderness to digital palpation, or pressure-pain
threshold, perhaps due to a diﬀerent molecular mecha-
nism behind each pain entity.
Alstergren et al [5] showed that TMJ synovial ﬂuid
level of 5-HT is associated with pain intensity perceived
on movement and to decreased mandibular mobility
in patients with systemic inﬂammatory disorders. Voog
et al [6] showed that intra-articular injection of the
5-HT3 receptor antagonist granisetron in the TMJ re-
duces resting as well as movement pain intensity and in-
creases pressure-pain threshold in patients with rheuma-
toid arthritis. These two studies indicate that peripheral
serotonergic mechanisms are involved in the modulation
of pain and hyperalgesia/allodynia in systemic inﬂamma-
tory joint disorders. However, no study has reported the
inﬂuence of 5-HT level in the TMJ or blood on the eﬀect
of local glucocorticoid treatment.
Theaimsofthisstudywerethereforetoinvestigatethe
inﬂuence of synovial ﬂuid and blood levels of 5-HT on
the eﬀects by intra-articular injections of glucocorticoid
on pain and allodynia of the TMJ in patients with chronic
and systemic inﬂammatory disorders of the TMJ.
MATERIAL AND METHODS
Patients
One male and nineteen female patients with inﬂam-
matory TMJ disorders participated (Table 1). Inclusion
criteria were diagnosis of seropositive or seronegative RA
(n = 3a n dn = 5, respectively), ankylosing spondyli-
tis (n = 3), osteoarthritis (n = 1), psoriatic arthropathy2005:4 (2005) Serotonergic Mechanisms Inﬂuence TMJ Arthritis 195
Table 1. Pretreatment data of 20 patients with chronic inﬂammatory joint disease subjected to intra-articular glucocorticoid injec-
tions. IQR = 25th–75th percentile; n is the number of patients.
Background variables Median IQR n
Age (years) 50 18 20
Duration of general joint involvement (years) 10 14 20
Duration of local TMJ involvement (years) 5 11 19
Number of involved joints (1–9) 6 3 20
Thrombocyte particle concentration (109/L) 289 95 14
(n = 1), chronic unspeciﬁc polyarthritis (n = 2), systemic
lupuserythematosus(n = 1),Sj¨ ogren’ssyndrome(n = 1),
common variable immunodeﬁciency (n = 1), or Marfan’s
syndrome (n = 2). The diagnosis of RA was determined
according to the criteria of American College of Rheuma-
tology [7]. The diagnosis of TMJ inﬂammatory disorder
due to polyarthritis was determined according to the di-
agnostic classiﬁcation by the American Academy of Oro-
facial Pain [8]. An exclusion criterion was intra-articular
glucocorticoid treatment of the TMJ within 3 months.
All patients were referred to the clinic from rheuma-
tologists or general medical practitioners. Eight patients
used nonsteroidal antiinﬂammatory drugs (naproxen), 5
patients oral glucocorticoid (methylprednisolone), 7 pa-
tients disease-modifying antirheumatic drugs (sulfazala-
sine, methotrexate, inﬂiximab), and 4 patients had no
current (systemic) medical treatment.
The study was approved by the local Ethical Commit-
tee at Karolinska University Hospital in Huddinge, Swe-
den (142/02 and 176/91).
Painintensityratings
The patients were asked about pain in nine joint re-
gions besides the TMJ (neck, shoulders, elbows, hands,
upper back, lower back, hips, knees, and feet; max
score 9).
A 100mm visual analog scale with end-points de-
noted “no pain” (0mm) and “worst pain ever experi-
enced” (100mm) was used to assess the current TMJ pain
intensity on each side at rest and on maximum voluntary
mouth opening.
Thenumberofmandibularmovementsthatprovoked
painintheTMJ(maximummouthopening,laterotrusion
to both sides, and protrusion) was counted for each side
(score 0–4).
Tenderness to digital palpation of the lateral and pos-
terior aspects of the TMJ on each side was assessed. On
each side and aspect one unit was scored if the patient re-
ported tenderness and two units if the palpation caused a
pain reﬂex. The total score was also counted (score 0–4).
The pressure-pain threshold was recorded over the
palpable lateral pole of the TMJ condyle with the pa-
tient’s mouth closed and over glabella. The pressure-pain
threshold was deﬁned as the minimum pressure needed
to evoke a painful sensation recognizable by the subjects.
The pressure-pain threshold was assessed by a hand-held
electronic pressure algometer (Somedic Production AB,
Sollentuna, Sweden) consisting of a pressure transducer
probe connected to a pistol grip with a display unit. The
tipofthepressuretransducerhasaﬂat,circularrubbertip
with an area of 1.0cm 2. A linearly increasing pressure rate
(50kPa/s) was applied until the subject responded to the
ﬁrst pain sensation by pressing a button on a device con-
nected to the probe that froze the current pressure-pain
threshold level on the display.
Synovialﬂuidsamplingfromthe
temporomandibularjoint
TMJ anesthesia was achieved by blocking the auricu-
lotemporal nerve with 2.0mL 2% lidocaine (Xylocain,
Astra-Zeneca, S¨ odert¨ alje, Sweden). The TMJ was punc-
tured with a standard disposable needle (diameter =
0.65mm) inserted into the posterior part of the upper
joint compartment. TMJ synovial ﬂuid samples were ob-
tained by washing the joint cavity with saline using a push
and pull technique [9]. The washing solution, consist-
ing of 78% saline (NaCl 9mg/mL, Pharmacia Upjohn,
Uppsala, Sweden) and 22% hydroxocobalamin (Behepan
1mg/mL; Pharmacia Upjohn), was slowly injected into
the posterior part of the upper joint cavity with approx-
imately 1mL at a time and then aspirated. The total vol-
ume of the washing solution injected was 4mL. The hy-
droxocobalamin was included in order to determine the
volume of synovial ﬂuid recovered in the aspirate by com-
paring the spectrophotometric absorbance of the aspirate
with that of the washing solution. The synovial ﬂuid level
wasthencalculated.Onlysamplesthatfulﬁlledpreviously
established sample quality criteria were included in the
statistical analysis [10].
Bloodsampling
Venous blood was collected in a sodium citrate tube
(0.105mol/L) to determine the erythrocyte sedimenta-
tion rate and in an EDTA tube that was immediately
cooled and centrifuged (1500g for 30 minutes at +4◦C)
a n dt h e nf r o z e n( −70◦C), and later examined for 5-HT
in plasma. In addition, venous blood was collected with-
out additives for analysis of serum concentrations of 5-
HT, thrombocyte particle count, and C-reactive protein.
These tubes were left at room temperature for 60 min-
utes for coagulation and thereafter centrifuged (1500g
for 10 minutes at +4◦C). The serum was then removed
and frozen (−70◦C) until analysis. Time from freezing196 Lars Fredriksson et al 2005:4 (2005)
to analysis varied between 1 and 6 months for the blood
samples.
Drug
The acetate ester of methylprednisolone (40mg/mL)
with lidocaine hydrochloride (10mg/mL) added (Depo-
Medrol cum lidocaine; Pﬁzer AB, T¨ aby, Sweden) was in-
jectedinavolumeof0.7mLintotheupperjointcompart-
ment.
Treatmentandexaminationschedule
The patients were examined before and after treat-
ment. The median (IQR) interval between the ﬁrst and
second examinations of 38 (52) days. At the ﬁrst exami-
nation, glucocorticoid was injected into the TMJ after the
synovial ﬂuid sampling and at the second examination
only synovial ﬂuid sampling was performed.
Analysisofserotonin
Serum and plasma 5-HT levels were analyzed by a
commercially available EIA-kit (Immunotech A Coulter
Company, Marseille, France) with a detection limit of
0.5nmol/L.Theintra-assaycoeﬃcientofvariationforthis
assay is less than 9.4 and the interassay less than 9.9% ac-
cording to the manufacturer.
The concentration of synovial ﬂuid levels of 5-HT
was analyzed by using the same kit but it was modi-
ﬁed to be applicable at concentrations between 1.6a n d
5000nmol/L.Tocompensateforhydroxocobalamininter-
actions with the assays, the synovial ﬂuid aspirates were
read against a standard curve with hydroxocobalamin in-
cluded [9, 10]. The small hydroxocobalamin interaction
was completely compensated for by this procedure.
Statisticalanalysis
Synovialﬂuidsamplesfrombothoccasionswereavail-
able from one TMJ on each patient and the clinical and
synovialﬂuiddatafromthissidewereusedintheanalysis.
Thecentraltendency andthevariation ofthevariablesare
presented as median and interquartile range (IQR; 75th–
25th percentile). The signiﬁcances of the diﬀerences be-
tween the variables before and after treatment were calcu-
lated by the Wilcoxon test. Spearman’s ranked correlation
test was used to calculate the signiﬁcance of the correla-
tions between the variables. A probability level below .05
was considered as signiﬁcant.
RESULTS
Table 2 shows the pretreatment and follow-up values
of the clinical variables and synovial ﬂuid levels of 5-HT.
Erythrocyte sedimentation rate (normal: < 28mm), C-
reactive protein (normal: < 10mg/L), and thrombocyte
particle concentration (normal: 150–400 109/L) were ab-
normal in 0%, 20%, and 14% of the patients.
Changesafterglucocorticoidtreatmentinrelationto
pretreatmentserotoninlevels
Serotonin was detectable in the synovial ﬂuid from 11
patients before treatment and in 12 after. The pretreat-
ment synovial ﬂuid level of 5-HT was negatively corre-
lated to the change in TMJ pain intensity at rest, which
decreased signiﬁcantly (P = .028), and TMJ pain inten-
sity on maximum mouth opening after treatment, that is,
a high pretreatment level of 5-HT was associated with a
decrease of TMJ pain intensity at rest (rs =− 0.52, n = 20,
P = .018; Figure 1a) and on maximum mouth opening
(rs =− 0.57, n = 13, P = .041; Figure 1b). The pretreat-
ment synovial ﬂuid level of 5-HT was also negatively cor-
related to the change in synovial ﬂuid 5-HT (rs =− 0.55,
n = 20,P = .012),whichmeansthathighpretreatment5-
HT was associated with decrease of 5-HT after treatment.
The pretreatment plasma level of 5-HT was above the
normal limit (15nmol/L) in 9 out of 10 patients before
treatment and in 3 out of 6 after treatment and it was
correlated to the level of C-reactive protein (rs = 0.66,
n = 10, P = .038). The pretreatment plasma level of
5-HT correlated to change in TMJ pain intensity at rest
(rs = 0.66, P = .040, n = 10; Figure 2a) and pressure-pain
threshold after treatment (rs = 0.83, n = 10, P = .003;
Figure 2b), that is, a high pretreatment level of 5-HT was
associated with an increase of resting pain and pressure-
pain threshold of the TMJ. The pretreatment thrombo-
cyte count was likewise positively correlated to change in
pressure-pain threshold (rs = 0.59, n = 14, P = .024).
Relationbetweenchangesafter
glucocorticoidtreatment
The change in serum level of 5-HT was correlated to
the change in number of painful mandibular movements
(rs = 0.77, n = 9, P = .014).
The change in TMJ resting pain was positively cor-
related to change in pain intensity on maximum mouth
opening (rs = 0.74, n = 13, P = .004). The signiﬁcant
decrease (P = .028) in lateral tenderness to palpation
was negatively correlated to the change in pressure-pain
threshold over the TMJ (rs =− 0.50, n = 20, P = .026;
Figure 3a) as well as over the glabella (rs =− 0.63, n = 14,
P = .016; Figure 3b), that is, a decrease in TMJ tenderness
wasassociatedwithanincreaseinpressure-painthreshold
at both sites.
Pretreatmentrelations
The synovial ﬂuid level of 5-HT was signiﬁcantly cor-
related to neither plasma (rs =− 0.14, n = 10, P = .680)
nor serum level of 5-HT (rs =− 0.37, n = 14, P = .190).
The serum level of 5-HT was positively correlated to the
plasma level of 5-HT (rs = 0.93, n = 9, P<. 001).
The serum level of 5-HT was positively correlated
to C-reactive protein (rs = 0.67, n = 13, P = .012),
while plasma level of 5-HT was positively correlated to C-
reactive protein and thrombocyte particle concentration
(rs = 0.66, n = 13, P = .038, and rs = 0.68, n = 9,2005:4 (2005) Serotonergic Mechanisms Inﬂuence TMJ Arthritis 197
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Figure 1. (a) Changes in temporomandibular joint (TMJ) resting pain intensity after intra-articular glucocorticoid treatment in
9 patients with undetectable (< 0.5nmol/L) and 11 patients with detectable pretreatment levels of serotonin (5-HT) in the TMJ
synovial ﬂuid and chronic inﬂammatory joint disease. There was a negative correlation between 5-HT and change in resting pain
after treatment (rs =− 0.52, n = 20, P = .018). (b) Changes in TMJ pain intensity on mouth opening in 8 patients with undetectable
(< 0.5nmol/L) and 5 patients with detectable pretreatment levels of 5-HT in TMJ synovial ﬂuid and chronic inﬂammatory joint
disease. There was a negative correlation between 5-HT and change in pain intensity on mouth opening after treatment (rs =− 0.57,
n = 13, P = .041).
P = .045). C-reactive protein was also correlated to num-
ber of painful mandibular movements (rs = 0.64, n = 15,
P = .010).
The thrombocyte count was correlated to plasma level
of 5-HT (rs = 0.68, n = 9, P = .044).
Tenderness to lateral palpation was negatively corre-
lated to pressure-pain threshold of the TMJ (rs =− 0.68,
n = 20, P<. 001) as well as over the glabella (rs =− 0.81,
n = 14, P<. 001). Pressure-pain threshold of the TMJ
was correlated to pressure-pain threshold of the over the
glabella (rs = 0.79, n = 14, P<. 001).
DISCUSSION
This study shows that the changes in TMJ pain after
intra-articular treatment with glucocorticoid are partly
determined by pretreatment 5-HT in TMJ synovial ﬂuid
and plasma in chronic arthritids of systemic nature, that
is, these diseases seem to include local as well as systemic
serotonergic mechanisms. It also shows that the changes
in pressure-pain threshold over the TMJ are inﬂuenced by
pretreatment systemic 5-HT.
Patients with detectable pretreatment levels of syn-
ovialﬂuid5-HTexperiencedalargerdecreaseofTMJpain
intensityatrestthanthosewithout,andlikewise,morere-
l i e ff r o mT M Jp a i no nm o v e m e n t .T h i si ss u p p o r t e db y
Alstergren et al [5] who found that a high synovial ﬂuid
level of 5-HT was associated with pain on mandibular
movements. Patients with low plasma 5-HT levels had a
larger decrease in TMJ resting pain than those with high
levels and those with reduced serum levels of 5-HT after
treatment had decreased number of painful mandibular
movements. Plasma and serum levels of 5-HT were in
turn correlated with C-reactive protein before treatment,
which indicates that both are associated with the systemic
inﬂammatory activity. In a previous study, high serum
levelof5-HThasbeenassociatedwithpainfulmandibular
movements as well as pain on maximum mouth opening
[11].Theﬁndingsinthisstudythusindicatealocalaswell
as systemic inﬂuence of 5-HT on the changes in TMJ pain
induced by local glucocorticoid treatment. However, the
inﬂuence of local and systemic 5-HT has opposite direc-
tions, that is, detectable synovial ﬂuid 5-HT is associated
with pain relief, while high plasma levels of 5-HT are as-
sociated with less reduction of pain.
TMJ resting pain decreased signiﬁcantly in this pa-
tient sample after intra-articular injection of glucocorti-
coid, which has been demonstrated in several other stud-
ies [1, 12, 3]. This eﬀect seems to be inﬂuenced by free
5-HT in two compartments, that is, synovial ﬂuid and
blood. It can be hypothesized that 5-HT in both com-
partments may independently result in sensitization or
activation of nociceptive aﬀerents [13] or act more in-
directly by activating other cells like T lymphocytes or
monocytes/macrophages [14, 15], which in turn release
algogenic mediators like TNF-α or IL-1β. Serotonin may
also modulate or amplify neurogenic inﬂammation in
chronic pain conditions by the 5-HT3 receptor, which
results in local release of, for example, substance P
[14, 16]. Intravenous treatment with the 5-HT3 recep-
tor antagonist tropisetron reduced the serum substance
P levels in ﬁbromyalgia patients who responded to pain198 Lars Fredriksson et al 2005:4 (2005)
Table 2. General and local (temporomandibular joint; TMJ) disease activity before and 5 weeks after intra-articular administration
of glucocorticosteroid in 20 patients with chronic inﬂammatory joint disease. Pain intensity was assessed with a 100 mm visual analog
scale (VAS), the number of mandibular movements that provoked pain in the TMJ (maximum mouth opening, laterotrusion to
both sides and protrusion) was counted for each side, tenderness to digital palpation of the lateral and posterior aspects of the TMJ
on each side was recorded as one unit if the patient reported tenderness and two units if the palpation caused a pain reﬂex, and the
pressure-painthresholdwasrecordedoverthepalpablelateralpoleoftheTMJcondyleandoverglabella;IQR = 25th–75thpercentile,
n denotes number of patients, % > 0 denotes observations percent exceeding 0, and na denotes not applicable.
Clinical variables
Pretreatment Follow-up
Median IQR n % > 0 Median IQR n % > 0 P
General disease activity
General joint pain intensity (VAS score) 46 33 20 100 30 36 15 87 —
Erythrocyte sedimentation rate (mm/ﬁrst h) 9 11 16 na 18 16 15 na —
C-reactive protein (mg/L) 0 0 16 20 0 12 13 38 —
TMJ pain intensity
At rest (VAS score) 50 41 20 95 25 42 20 80 .028
Upon maximal mouth opening (VAS score) 51 40 13 100 37 40 13 92 —
Number of painful mandibular movements 3 1 20 90 2 2 20 80 —
Tenderness to digital palpation
Lateral — 1 1 20 95 1 1 20 60 .028
Posterior — 1 1 20 65 1 1 20 50 —
Pressure-pain threshold
Temporomandibular joint (kPa) 136 95 20 na 141 104 20 na —
Glabella (kPa) 240 94 14 na 237 119 14 na —
Serotonin levels
Synovial ﬂuid (nmol/L) 16 126 20 55 13 667 20 65 —
Serum (nmol/L) 898 506 14 100 670 547 11 91 —
Plasma (nmol/L) 37 23 10 100 17 20 6 100 —
relief, which indicates that systemic serotonergic mecha-
nisms interact with peripheral neurogenic inﬂammatory
activity [17]. Both peripheral and central 5-HT3 receptors
are pronociceptive and the peripheral 5-HT3 receptor in-
volves speciﬁc primary aﬀerent nociceptors [13].
In addition to the 5-HT3 receptor serotonin may act
via other peripheral pain-related receptors in inﬂamma-
tory conditions. In experimental adjuvant-induced in-
ﬂammation of the hind paw of the rat, increased 5-HT2A
receptor mRNA was expressed in calcitonin gene-related
peptide-synthesizing dorsal root ganglion neurons [18].
Systemic administration of 5-HT2A receptor antagonist
then produced analgesic eﬀects on thermal hyperalgesia
caused by the peripheral inﬂammation.
T h es o u r c eo fs y n o v i a lﬂ u i d5 - H Tc a nb ea s s u m e dt o
be thrombocytes or mast cells that accumulate and acti-
vate in the arthritic synovial membrane or ﬂuid [19, 20].
The level of free 5-HT in plasma is determined by the
equilibrium between free 5-HT and 5-HT stored in circu-
lating thrombocytes as indicated by the relation between
thrombocyte particle count and 5-HT in plasma in this
study and serum in a previous study [11]. The thrombo-
cytes become activated by systemic inﬂammation, as in-
dicated by their relation to both C-reactive protein and
plasma 5-HT, which increases the level of free 5-HT. The
mode of action of glucocorticoid with regard to 5-HT
cannot be determined by the data in this study, but glu-
cocorticoid injected into the joint may inhibit release of
5-HT from thrombocytes or mast cells in the synovial
membrane. This would result in a decrease of 5-HT in
the synovial ﬂuid after treatment, which was not found
in this study. Another more likely explanation according
to the present results is that the 5-HT is an intermedi-
ate mediator and bind to receptors on cells such as T
lymphocytes or monocytes/macrophages, which in turn
are activated to release inﬂammatory mediators with al-
gogenic properties. These cells have intracellular gluco-
corticoid receptors to which glucocorticoids bind and ac-
tivate to inhibit the expression of genes for, for exam-
ple, proinﬂammatory algogenic cytokines [2]. These lat-
ter explanations are in agreement not only with the ﬁnd-
ing that TMJ pain is more reduced if detectable levels of
5-HT are present in the synovial ﬂuid before treatment,
but also with the ﬁnding that the synovial ﬂuid level per
se is not changed by the treatment. The lack of correla-
tion between synovial ﬂuid and plasma 5-HT levels fur-
ther indicates that the eﬀects of 5-HT in the synovial ﬂuid
and unbound 5-HT in the blood, which both may be2005:4 (2005) Serotonergic Mechanisms Inﬂuence TMJ Arthritis 199
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Figure 2. (a) Change in temporomandibular joint (TMJ) resting pain intensity after intra-articular glucocorticoid treatment in 7
patients with lower level than median group (< 37nmol/L) and 3 patients with higher level than median pretreatment plasma levels
(≥ 37nmol/L) of serotonin (5-HT) in patients with chronic inﬂammatory joint disease. There was a positive correlation between 5-
HT and change in resting pain intensity after treatment (rs = 0.66, n = 10, P = .040). (b) Change in temporomandibular joint (TMJ)
pressure-pain threshold after intra-articular glucocorticoid treatment in 5 patients with lower level than median group (< 37nmol/L)
and 5 patients with higher level than median pretreatment plasma levels (≥ 37nmol/L) of serotonin in patients with chronic inﬂam-
matory joint disease. There was a positive correlation between 5-HT and change in pressure-pain threshold after treatment (rs = 0.83,
n = 10, P = .003).
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Figure 3. Relation between change in temporomandibular joint (TMJ) tenderness to lateral digital palpation and change in (a) TMJ
and (b) glabella pressure-pain thresholds after intra-articular glucocorticoid treatment in patients with chronic inﬂammatory joint
disease. (a) Ten patients had a decrease and 10 had no change or an increase of TMJ tenderness to lateral digital palpation. There was
a negative correlation between change in TMJ tenderness to lateral digital palpation and change in TMJ pressure-pain threshold after
treatment (rs =− 0.50, n = 20, P = .026). (b) Five patients had a decrease and 9 had no change or an increase of TMJ tenderness to
lateral digital palpation. There was a negative correlation between change in TMJ tenderness to lateral digital palpation and change in
glabella pressure-pain threshold after treatment (rs =− 0.63, n = 14, P = .016).
derived from, for example, activated thrombocytes, are
independent. The pain-relieving eﬀect of intra-articular
glucocorticoid in the TMJ seems to be reduced if high
unbound levels of 5-HT derived from the circulation are
available in the synovial tissues, which occurs when the
systemic inﬂammatory activity is high. In this condition,
the number of inﬂammatory cells that can be activated
by 5-HT will increase and the injected glucocorticoid may
notsuﬃcetoblocktheiractivityandtoprovidepainrelief
for 5 weeks. The higher systemic inﬂammatory activity,200 Lars Fredriksson et al 2005:4 (2005)
the more important this mechanism will be since 5-HT in
plasma is correlated to C-reactive protein. The best prog-
nosis for pain relief by intra-articular glucocorticoid ad-
ministration, according to this study, can therefore be ex-
pected for patients with a combination of high level of 5-
HT in synovial ﬂuid and low level in plasma, that is, high
local inﬂammatory activity but low systemic activity.
The changes in pressure-pain threshold of the TMJ
seem to be inﬂuenced by 5-HT in plasma since a high pre-
treatment level was associated with increase of the thresh-
old and low level with decrease. The blood level and not
thesynovialﬂuidlevelof5-HTthereforeseemstobeapu-
tative predictor for the eﬀect of intra-articular glucocorti-
coid treatment on pressure-pain threshold over the TMJ.
High level of 5-HT in plasma and high systemic inﬂam-
matory activity may hence predict increase of pressure-
pain threshold and reduced relief of TMJ resting pain as
a likely outcome of intra-articular glucocorticoid treat-
ment. These contrasting results indicate diﬀerent pain
mechanisms behind TMJ resting pain and pressure-pain
threshold over the TMJ. The relation between changes in
pressure-pain threshold over the TMJ and lateral tender-
ness to digital palpation of the TMJ indicates that lateral
tenderness has a partly diﬀerent mechanism than TMJ
resting pain, which is further illustrated by the relation
between lateral tenderness of the TMJ and pressure-pain
threshold over glabella.
As y s t e m i ce ﬀect by the intra-articular glucocorticoid
treatment cannot be excluded but is probably weak since
neither pain in general, pressure-pain threshold of the
glabella, erythrocyte sedimentation rate, nor C-reactive
protein was signiﬁcantly changed after treatment.
Inconclusion,thisstudyshowsthatlocalandsystemic
serotonergic mechanisms partly determine the eﬀect of
intra-articular glucocorticoid treatment on TMJ pain in
patients with chronic TMJ arthritis of systemic nature,
while change in pressure-pain threshold over the TMJ is
inﬂuenced by systemic serotonergic mechanisms as part
of the systemic inﬂammatory condition.
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